Lenalidomide in Subject With Low and Intermediate-1 Risk MDS and Without Chromosome 5 Abnormality.

The recruitment status of this study is unknown because the information has not been verified recently.
Verified October 2012 by Groupe Francophone des Myelodysplasies.
Recruitment status was  Active, not recruiting
Sponsor:
Collaborators:
Celgene Corporation
Roche Pharma AG
Information provided by (Responsible Party):
Groupe Francophone des Myelodysplasies
ClinicalTrials.gov Identifier:
NCT01718379
First received: October 23, 2012
Last updated: March 19, 2014
Last verified: October 2012
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is ongoing, but not recruiting participants.
  Estimated Study Completion Date: January 2016
  Estimated Primary Completion Date: June 2015 (Final data collection date for primary outcome measure)
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):